Evidence map›Paper›PMID 34500240›Full record

ArticleDrug and alcohol dependence2021

Tolerance and dependence following chronic alprazolam treatment in rhesus monkeys: Role of GABA

Angela N Duke, V V N Phani Babu Tiruveedhula, Dishary Sharmin, Daniel E Knutson, James M Cook, Donna M Platt, James K Rowlett

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. GABAergic compounds for the treatment of alcohol use disorder.International review of neurobiology · 2024
    Review
  6. Article
  7. Article
  8. GABAFrontiers in psychiatry · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Angela N DukeHarvard Medical School, New England Primate Research Center, One Pine Hill Drive, Southborough, MA, 01772, USA.
V V N Phani Babu TiruveedhulaDepartment of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee Institute of Drug Discovery, Milwaukee, WI, 53211, USA.
Dishary SharminDepartment of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee Institute of Drug Discovery, Milwaukee, WI, 53211, USA.
Daniel E KnutsonDepartment of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee Institute of Drug Discovery, Milwaukee, WI, 53211, USA.
James M CookDepartment of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee Institute of Drug Discovery, Milwaukee, WI, 53211, USA.
Donna M PlattHarvard Medical School, New England Primate Research Center, One Pine Hill Drive, Southborough, MA, 01772, USA; Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA.
James K RowlettHarvard Medical School, New England Primate Research Center, One Pine Hill Drive, Southborough, MA, 01772, USA; Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA. Electronic address: jrowlett@umc.edu.
University of Wisconsin–Milwaukee · USNew England Biolabs (United States) · USState Street (United States) · US

Funding

ANXIOLYTIC EFFECTS AND ABUSE OF BZ RECEPTOR LIGANDSR01DA011792 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI ROWLETT, JAMES K · 1998 to 2024
$7.8M
Tolerance and Physical Dependence after Chronic Benzodiazepine TreatmentR01DA043204 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI JAMES K ROWLETT · 2017 to 2026
$4.3M
GABA-A receptor subtype mechanisms and the abuse-related effects of alcoholR01AA029023 · NIAAA · UNIVERSITY OF MISSISSIPPI MED CTR · PI PLATT, DONNA M · 2020 to 2024
$2.4M
Synthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic PainR01NS076517 · NINDS · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2012 to 2015
$1.3M
NIAAA NIH HHS R01 AA029023NIDA NIH HHS R01 DA011792NIDA NIH HHS R01 DA043204NINDS NIH HHS R01 NS076517
6 · The paper itself

Abstract

backgroundTo assess GABA

methodsFour female rhesus monkeys (Macaca mulatta) were implanted with chronic intravenous catheters and administered alprazolam (1.0 mg/kg every 4 h). Following 14+ days of chronic alprazolam, acute administration of selected doses of non-selective and subtype-selective ligands were substituted for, or administered with, alprazolam, followed by quantitative behavioral observations. The ligands included alprazolam and midazolam (positive modulators, non-selective), zolpidem (positive modulator, preferential affinity for α1-containing GABA

resultsAcutely, alprazolam and midazolam both induced observable ataxia along with a mild form of sedation referred to as "rest/sleep posture" at a lower dose (0.1 mg/kg, i.v.), whereas at a higher dose (1.0 mg/kg, i.v.), induced deep sedation and observable ataxia. With chronic alprazolam treatment, observable ataxia and deep sedation were reduced significantly, whereas rest/sleep posture was unchanged or emerged. Zolpidem showed a similar pattern of effects, whereas no behaviors engendered by HZ-166 were changed by chronic alprazolam. Administration of βCCT, but not HZ-166, resulted in significant withdrawal signs.

conclusionsThese results are consistent with a role for α1-containing GABA

Indexed as

AlprazolamDrug ToleranceReceptors, GABA-ASubstance Withdrawal SyndromeAnimalsBenzodiazepinesFemaleMacaca mulattaMidazolamZolpidemAlprazolamBenzodiazepinesMidazolamReceptors, GABA-AZolpidemAlprazolamBenzodiazepineDependenceGABA(A) subtypePrimateTolerance

Identifiers

PMID34500240
PMCPMC8595788
OpenAlexW3198101455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.